COMPASS Pathways plc (NASDAQ:CMPS) Q3 2023 Earnings Call Transcript

Page 6 of 6

Dr. Guy Goodwin: If I could just add, I think the analogy with CAR-T isn’t quite right. I mean our trials are more difficult to do than clinical practice. And that really makes a difference. If you talk to people who are providers of clinical services, they really don’t have experience or appetite to do clinical trials. But they do have an appetite to provide a good service to an [Indiscernible] patient population. So we have literally had conversations with providers who are very keen to think about how we could look at implementing treatment in their centre, but really wouldn’t dream of offering to do a clinical trial because it’s just a different kind of activity. And bear in mind, when you give a clinical trial, you’re offering people quite a high chance of failure because of the control arm.

And that has to be something that the investigator understands and can live with. And for many clinicians, it’s really against their human spirit. They really don’t like that. So people who do trials are unusual. And getting those centres is tough. Getting people to deliver the same treatment in real life, I think, will be different and easier compared to clinic trial.

Operator: That concludes the question-and-answer session. At this time, I would like to turn the call back to management for closing remarks.

Stephen Schultz: Thanks very much. So once again, thank you, everyone, for participating on today’s call. And as we said, with the private placement financing that we raised in August, that’s significant financing, which has the potential for a further financial vehicle as well, we’re in a position of strength to continue to execute confidently on our Phase III program in TRD. We look forward to updating you with PTSD data at the end of this year. And as we’ve always said, with further milestones in next year. Again, thank you very much all for your attention today.

Operator: Thank you for your participation in today’s conference. This does conclude the program. You may now disconnect.

Follow Compass Pathways Plc (NASDAQ:CMPS)

Page 6 of 6